The case for & against
Bull & Bear analysis
Bearish
Jaguar Health, Inc. (NASDAQ: JAGX) is a biopharmaceutical company specializing in developing plant-based therapies for gastrointestinal disorders, particularly in the rare disease market. The company focuses on its flagship product, Crofilomer, which addresses severe conditions such as Microvillous Inclusion Disease (MVID) and Short Bowel Syndrome (SBS). With a strategic emphasis on obtaining regulatory approvals and partnerships, Jaguar aims to capture significant market potential in an area characterized by few treatment options.
Bull says
- ↑Q1 2026 net revenue soared 816% YoY to $20.2M, driven by FuturePak licensing of Crofilomer.
- ↑Secured $16M upfront in non-dilutive licensing deals, preserving equity while funding clinical development.
- ↑Clinical trials show up to 37% reduction in parenteral nutrition for MVID patients, boosting regulatory prospects.
- ↑Short bowel syndrome market expected to reach $8B by 2033, underscoring long-term growth potential.
- ↑Strong liquidity supports short-term obligations; book-to-price ratio suggests potential undervaluation.
- ↑Low interest-rate sensitivity may cushion stock amid rising rate environment.
Bear says
- ↓Q1 2026 net loss widened to $7.1M, straining operating cash flow.
- ↓Prescription revenue tumbled 62% QoQ to $1.2M, highlighting inconsistent sales performance.
- ↓Heavy reliance on licensing agreements risks future funding if partner deals falter.
- ↓Regulatory delays or failure to secure FDA breakthrough designation could derail revenue projections.
- ↓High stock volatility and weak profitability factors increase downside risk.
- ↓Limited institutional ownership and negative revisions signal low investor conviction.
Investment themes with JAGX
Pharmaceuticals↑ +0.79%
Drug development driving global healthcare solutions
LLY · JNJ · MRK
Most Shorted Stocks↑ +0.88%
Stocks with highest short interest
LITE · AXTI · NVTS
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 06-14-2026bearish
Transcript signals
Bull points
- This is in contrast to dispensed prescriptions for Mitessi, Crofilamer, which I am pleased to announce increased in the first quarter of 2025 versus the first quarter of 2024 by approximately 2%. This is an indication of increased demand and that more patients are receiving treatment for HIV-related diarrhea from Mitessi.
- The initial proof of concept results that we issued on April 30th showed that crofilomer reduced TPN in the first MVID patient to participate in the study by up to 27%.
- These initial results are potentially transformative for the patients and their caregiving community, it's not possible to overstate the significance of reduction in TPN.
Bear points
- The total net revenue for the company's prescription products was approximately $2.2 million in the first quarter of 2025, a decrease of approximately 6% versus the first quarter of 2024, revenue of $2.4 million, and 37% versus net fourth quarter 2024 revenue of $3.5 million.
- Loss from operations increased by 1.2 million from 8.2 million in the quarter ended March 31, 2024 to $9.4 million during the same period in 2025.
- Net loss attributable to common shareholders increased by approximately 1.2 million from 9.2 million in the quarter ended March 31, 2024 to 10.4 million in the same period in 2025.
Read full transcript analysis ›